Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 712

Sort by

Sort Order Select

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Oral Arginine Therapy As a Novel Adjuvant in the Management of Acute Pain in Children with Sickle Cell Anemia in Nigeria: A Randomized Placebo-Controlled Trial

Richard Onalo, FCPaed, Peter Cooper, FCPaed, Antoinette Cilliers, FCPaed, Uche Nnebe-Agumadu, FCPaed, Oluseyi Oniyangi, FCPaed, Damilare Oladimeji, MSc Statistics, Claudia R. Morris, MD

Blood (2019) 134 (Supplement_1): 613.

https://doi.org/10.1182/blood-2019-122510

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Xiaojuan Chen, BsN, MsN, Foong-Gwan Lee, BsN, Shi Hui Clarice Choong, MBBS, MRCP, Xiao-Shi Saw, BSc(Pharm), Lon-Wann Sai, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Hian Li Esther Hian Li Chan, MBBS, MRCP, FRCPATH, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Yen Lin Chee, MBBS, FRCPATH, PhD, Yee Mei Lee, BsN, MsN, PhD

Blood (2019) 134 (Supplement_1): 2152.

https://doi.org/10.1182/blood-2019-129858

Published: 2019

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Pratibha Bhatia, MSc, BSc, Sumeet Prakash Mirgh, MBBS,MDDM, Vishvdeep Khushoo, MBBS,MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Rayaz Ahmed, MDDM, Narendra Agrawal, MD DM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 3500.

https://doi.org/10.1182/blood-2019-131763

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM

Blood (2019) 134 (Supplement_1): 2914.

https://doi.org/10.1182/blood-2019-128755

Published: 2019

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD

Blood (2019) 134 (Supplement_1): 2828.

https://doi.org/10.1182/blood-2019-123279

Published: 2019

Journal Articles

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Manju Sengar, MD DM, Mounika Boppana, MD DM, Hasmukh Jain, MD DM, Vikram Gota, MD, Bhausaheb Bagal, MD DM, Anant Gokarn, MD, Murari Gujrar, MD, Madhavi Ambotkar, MD

Blood (2019) 134 (Supplement_1): 2600.

https://doi.org/10.1182/blood-2019-129948

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress

Claudia R. Morris, MD, Janet Figueroa, MPH, Amanda Watt, Kirshma Khemani, MD, Polly Kumari, MBBS, Morgan Barnett, MPH, Nitya Bakshi, MBBS, MS, Peter A. Lane, MD, Carlton Dampier, MD

Blood (2019) 134 (Supplement_1): 995.

https://doi.org/10.1182/blood-2019-122983

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

NARROW

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Oral Arginine Therapy As a Novel Adjuvant in the Management of Acute Pain in Children with Sickle Cell Anemia in Nigeria: A Randomized Placebo-Controlled Trial

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only